Abstract
PET/MR imaging has the potential to markedly alter pancreatic care in both the malignant, and premalignant states with the ability to perform robust, high-resolution, quantitative molecular imaging. The ability of PET/MR imaging to monitor disease processes, potentially correct for motion in the upper abdomen, and provide novel biomarkers that may be a combination of MR imaging and PET biomarkers, offers a unique, precise interrogation of the pancreatic milieu going forward.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 345-362 |
| Number of pages | 18 |
| Journal | Magnetic Resonance Imaging Clinics of North America |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 2018 |
Funding
Disclosure: Dr T.A. Hope has received grant support from GE Healthcare ; Dr A.R. Guimaraes is affiliated with Siemens Speaker’s Bureau, AGFA Imaging, Merck Pharmaceuticals, Inc; Dr N. Mallak has nothing to disclose.
| Funders |
|---|
| GE Healthcare |
Keywords
- DOTATATE
- Neuroendocrine tumor
- PET/MR imaging
- Pancreas
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'PET/MR Imaging of the Pancreas'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS